Overview

Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?

Status:
Completed

Trial end date:
2008-04-01

Target enrollment:

Participant gender:

Summary

The major objective of this proposal is to test the hypothesis that the addition of divalproex sodium to an atypical antipsychotic drug other than clozapine will significantly improve: a) cognition; and b) psychopathology (positive, negative, and mood symptoms) in a double-blind, randomized trial of 6 weeks duration in patients with schizophrenia or schizoaffective disorder.

Phase:

Phase 4

Details

Lead Sponsor:

Vanderbilt University
Vanderbilt University Medical Center

Collaborators:

Abbott
National Alliance for Research on Schizophrenia and Depression

Treatments:

Antipsychotic Agents
Valproic Acid